Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries
| Autor: | Solans, M., Sanvisens, A., Ameijide, Alberto, Merino, S., Rojas, Dolores, Alemán, A., Banqueri, E., Chico, Matilde, Marcos, A.I., de Castro, Visitación, Gil, L., López de Munain, Arantza, Puigdemont, Montse, Sánchez, M.J., Perucha, J., Ruiz-Armengol, P., Chirlaque, María-Dolores, Guevara, M., Carulla, M., Marcos-Gragera, Rafael, Universitat Autònoma de Barcelona |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Male Time Factors Càncer -- Estadístiques Epidemiology Science Leucèmia mieloide Article Myeloproliferative disease Humans Registries Aged Aged 80 and over Multidisciplinary Myeloproliferative Disorders Cancer -- Statistics Incidence Tumors -- Espanya Middle Aged Health Surveys Leukemia Myeloid Acute Tumors -- Spain Myeloid leukemia Spain Myelodysplastic Syndromes Medicine Female Myelodysplastic syndrome |
| Zdroj: | Scientific Reports, 2022, vol. 12, art. núm. 323 Articles publicats (D-I) DUGiDocs – Universitat de Girona instname Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022) Scientific Reports Digibug. Repositorio Institucional de la Universidad de Granada |
| Popis: | This work was partially funded by the Josep Carreras Leukaemia Research Institute (Grant No.: FIJC1100); the Ministry of Science, Innovation and Universities, Carlos III Health Institute (ISCIII), Spain (Grant No.: PI15/00966); the Agency for Management of University and Research Grants, Government of Catalonia (Grant No.: 2017SGR00733); the CIBER of Epidemiology and Public Health (CIBERESP) (`Cohort-Real World Data' subprogram). Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002–2013 using harmonized data from 13 population-based cancer registries. Cases (n = 17,522) were grouped following the HAEMACARE groupings and 2013-European standardized incidence rates ( ASRE), incidence trends, and estimates for 2021 were calculated. ASRE per 100,000 inhabitants was 5.14 (95% CI: 5.00–5.27) for myeloproliferative neoplasms (MPN), 4.71 (95% CI: 4.59–4.84) for myelodysplastic syndromes (MDS), 3.91 (95% CI: 3.79–4.02) for acute myeloid leukemia, 0.83 (95% CI: 0.78–0.88) for MDS/MPN, 0.35 (95% CI: 0.32–0.39) for acute leukemia of ambiguous lineage, and 0.58 (95% CI: 0.53–0.62) for nototherwise specified (NOS) cases. This study highlights some useful points for public health authorities, such as the remarkable variability in incidence rates among Spanish provinces, the increasing incidence of MPN, MDS, and MDS/MPN during the period of study, in contrast to a drop in NOS cases, and the number of cases expected in 2021 based on these data (8446 new MNs). Josep Carreras Leukaemia Research Institute FIJC1100 Ministry of Science, Innovation and Universities, Carlos III Health Institute (ISCIII), Spain PI15/00966 Agency for Management of University and Research Grants, Government of Catalonia 2017SGR00733 CIBER of Epidemiology and Public Health (CIBERESP) ('Cohort-Real World Data' subprogram) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|